# Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation

> **NCT02961270** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 30 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Icotinib

## Key facts

- **NCT ID:** NCT02961270
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11
- **Primary completion:** 2017-12
- **Final completion:** 2018-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2016-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02961270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02961270, "Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02961270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*